{
  "main_header": {
    "sid": 487832,
    "name": "Kobo Biotech",
    "stock_name": "Kobo Biotech",
    "full_name": "Kobo Biotech Ltd",
    "name_url": "stocks-analysis/kobo-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "6.84",
    "chg": 0.13,
    "chgp": "1.94%",
    "dir": 1,
    "prev_price": "6.71",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531541,
    "symbol": "",
    "ind_name": "Commodity Chemicals",
    "ind_code": 11,
    "indexname": "India SENSEX",
    "isin": "INE881A01015",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "3.08 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/kobo-biotech-487832-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Kobo Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Poor Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kobo-biotech-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-poor-financial-trends-3929659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/KoboBiotechLtd_mojoScore_3929659.png",
        "date": "2026-04-02 08:23:57",
        "description": "Kobo Biotech Ltd, a micro-cap player in the commodity chemicals sector, has been downgraded from a Sell to a Strong Sell rating as of 1 April 2026. This decisive change reflects deteriorating fundamentals, poor valuation metrics, a negative financial trend, and weak technical signals, signalling heightened risk for investors amid ongoing operational challenges and market underperformance."
      }
    ],
    "total": 3,
    "sid": "487832",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/kobo-biotech-487832"
  },
  "announcements": [
    {
      "caption": "Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal",
      "datetime": "11-May-2026",
      "details": "Approval of Resolution Plan and receipt of Order from NCLT",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "15-Apr-2026",
      "details": "Compliance certificate under Reg. 74(5) of SEBI (DP) for the quarter ended 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Non-Applicability Of Large Entity Disclosure",
      "datetime": "15-Apr-2026",
      "details": "Intimation Regarding Non Applicability of Large Entity Disclosure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kobo Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 21 Sep 12",
          "dt": "2012-09-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kobo Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Poor Financial Trends

2026-04-02 08:23:57

Kobo Biotech Ltd, a micro-cap player in the commodity chemicals sector, has been downgraded from a Sell to a Strong Sell rating as of 1 April 2026. This decisive change reflects deteriorating fundamentals, poor valuation metrics, a negative financial trend, and weak technical signals, signalling heightened risk for investors amid ongoing operational challenges and market underperformance.

Read More

View All News